Moreover, the tumor weights of the NPTyr-C9AP group measured at the treatment endpoint were only 16.7% that of the PBS group, also demonstrating the enhanced therapeutic efficacy of NPTyr-C9AP compared to that of the NPTyr-CXCL9 (36.9% that of the PBS group) or NPTyr-αPD-L1 (29.5% that of the PBS group) groups (Fig. 4f). Here, CXCL9 is linked to neoplasm.